Ultrasensitive tumour-penetrating nanosensors of protease activity

Nature Biomedical Engineering

Volumn 1, Issue 4, 2017, Pages

  Kwon, Ester J ^a,b   Dudani, Jaideep S ^a,c   Bhatia, Sangeeta N ^a,b,d,e,f,g  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d USA   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85029919483     PISSN: None     EISSN: 2157846X     Source Type: Journal    
DOI: 10.1038/s41551-017-0054     Document Type: Article

References (48)

1. Etzioni, R. et al. The case for early detection. Nat. Rev. Cancer 3, 243-252 (2003).
2. SEER Cancer Statistics Review, 1975-2013 (National Cancer Institute, 2016); http://seer.cancer.gov/csr/1975-2013
3. Kanas, G. P. et al. Survival afer liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin. Epidemiol. 4, 283-301 (2012).
4. Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L. & Montz, F. J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20, 1248-1259 (2002).
5. Fader, A. N. et al. The prognostic signifcance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study. Gynecol. Oncol. 132, 560-565 (2014).
6. Shaukat, A. et al. Long-term mortality afer screening for colorectal cancer. N. Engl. J. Med. 369, 1106-1114 (2013).
7. Frangioni, J. V. New technologies for human cancer imaging. J. Clin. Oncol. 26, 4012-4021 (2008).
8. Hori, S. S. & Gambhir, S. S. Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations. Sci. Transl. Med. 3, 109ra116 (2011).
9. Henry, N. L. & Hayes, D. F. Cancer biomarkers. Mol. Oncol. 6, 140-146 (2012).
10. Kwong, G. A. et al. Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat. Biotechnol. 31, 63-70 (2013).
11. Warren, A. D., Kwong, G. A., Wood, D. K., Lin, K. Y. & Bhatia, S. N. Point-of-care diagnostics for noncommunicable diseases using synthetic urinary biomarkers and paper microfuidics. Proc. Natl Acad. Sci. USA 111, 3671-3676 (2014).
12. Koblinski, J. E., Ahram, M. & Sloane, B. F. Unraveling the role of proteases in cancer. Clin. Chim. Acta 291, 113-135 (2000).
13. Kwong, G. A. et al. Mathematical framework for activity-based cancer biomarkers. Proc. Natl Acad. Sci. USA 112, 12627-12632 (2015).
14. Kessenbrock, K., Plaks, V. & Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52-67 (2010).
15. Farina, A. R. & Mackay, A. R. Gelatinase B/MMP-9 in tumour pathogenesis and progression. Cancers 6, 240-296 (2014).
16. Wu, Z.-S. et al. Prognostic signifcance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int. J. Cancer 122, 2050-2056 (2008).
17. Deere, J. et al. Kinetics of enzyme attack on substrates covalently attached to solid surfaces: infuence of spacer chain length, immobilized substrate surface concentration and surface charge. Langmuir 24, 11762-11769 (2008).
18. Nagase, H. & Fields, G. B. Human matrix metalloproteinase specifcity studies using collagen sequence-based synthetic peptides. Peptide Sci. 40, 399-416 (1996).
19. Miller, M. A. et al. Proteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities. Integr. Biol. 3, 422-438 (2011).
20. Whitley, M. J. et al. A mouse-human phase 1 co-clinical trial of a protease-activated fuorescent probe for imaging cancer. Sci. Transl. Med. 8, 320ra4 (2016).
21. Desnoyers, L. R. et al. Tumor-specifc activation of an EGFR-targeting probody enhances therapeutic index. Sci. Transl. Med. 5, 207ra144 (2013).
22. Miller, M. A. et al. Predicting therapeutic nanomedicine efcacy using a companion magnetic resonance imaging nanoparticle. Sci. Transl. Med. 7, 314ra183 (2015).
23. Bertrand, N., Wu, J., Xu, X., Kamaly, N. & Farokhzad, O. C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66, 2-25 (2014).
24. Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).
25. Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010).
26. Hrkach, J. et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a diferentiated pharmacological profle. Sci. Transl. Med. 4, 128ra39 (2012).
27. Ruoslahti, E. Specialization of tumour vasculature. Nat. Rev. Cancer 2, 83-90 (2002).
28. Ruoslahti, E. & Bhatia, S. N. & Sailor, M. J. Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 188, 759-768 (2010).
29. Lin, K. Y., Kwon, E. J., Lo, J. H. & Bhatia, S. N. Drug-induced amplifcation of nanoparticle targeting to tumors. Nano Today 9, 550-559 (2014).
30. Pang, H.-B. et al. An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability. Nat. Commun. 5, 4904 (2014).
31. Fogal, V., Zhang, L., Krajewski, S. & Ruoslahti, E. Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res. 68, 7210-7218 (2008).
32. Dufour, A. et al. Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res. 71, 4977-4988 (2011).
33. Zurawski, V. R. et al. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol. Oncol. 30, 7-14 (1988).
34. Ren, Y., Hauert, S., Lo, J. H. & Bhatia, S. N. Identifcation and characterization of receptor-specifc peptides for siRNA delivery. ACS Nano 6, 8620-8631 (2012).
35. Drapkin, R. et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 65, 2162-2169 (2005).
36. Rankin, E. B. et al. AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res. 70, 7570-7579 (2010).
37. Alper, Ö. et al. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J. Natl Cancer Inst. 93, 1375-1384 (2001).
38. Brown, P. O. & Palmer, C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 6, e1000114 (2009).
39. Sugahara, K. N. et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16, 510-520 (2009).
40. Desgrosellier, J. S. & Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9-22 (2010).
41. Yao, M., Lam, E. C., Kelly, C. R., Zhou, W. & Wolfe, M. M. Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br. J. Cancer 90, 712-719 (2004).
42. Jackson, B. C., Nebert, D. W. & Vasiliou, V. Update of human and mouse matrix metalloproteinase families. Hum. Genomics 4, 194-201 (2010).
43. Sanman, L. E. & Bogyo, M. Activity-based profiling of proteases. Annu. Rev. Biochem. 83, 249-273 (2014).
44. Withana, N. P. et al. Labeling of active proteases in fresh-frozen tissues by topical application of quenched activity-based probes. Nat. Protoc. 11, 184-191 (2016).
45. Sugahara, K. N. et al. Coadministration of a tumor-penetrating peptide enhances the efcacy of cancer drugs. Science 328, 1031-1035 (2010).
46. Van Gorp, T. et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br. J. Cancer 104, 863-870 (2011).
47. Alcázar, J. L., Guerriero, S., Laparte, C, Ajossa, S. & Jurado, M. Contribution of power Doppler blood fow mapping to gray-scale ultrasound for predicting malignancy of adnexal masses in symptomatic and asymptomatic women. Eur. J. Obstet. Gynecol Reprod. Biol 155, 99-105 (2011).
48. Park, J.-H. et al Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small 5, 694-700 (2009).